Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Incre

Logo
Presented by

Thorsten Lorenz, Team Head Developability Assessment Biologics, Novartis and Beate Kern, Product Manager, NanoTemper

About this talk

Title: Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Increasing Complexity Presenter: Thorsten Lorenz, Team Head Developability Assessment Biologics, Novartis Early lead selection of biotherapeutics during preclinical development requires careful characterization of a variety of molecule properties to reduce the risk for encountering unexpected obstacles during technical development. The diversity and increasing complexity of new protein formats requires a change from former platform approaches often applied for antibodies, to project specific strategies. The developability assessment concept applied at Novartis combines information addressing various technical areas, such as expression, aggregation propensity, process fit, stability, physicochemical properties, etc. This integrated concept prior to lead selection provides a thorough, yet resource efficient approach to select suitable candidates.

Related topics:

More from this channel

Upcoming talks (28)
On-demand talks (300)
Subscribers (29500)
BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.